Prestigious award recognizes Dr. High’s contribution to improving children’s health through her gene therapy research, which began during her time at CHOP.

In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).

CHOP researchers found that levels of proteins in the plasma of patients with MIS-C are significantly dysregulated and share features with two other inflammatory syndromes.

Alexis Anne Thompson, MD, to fulfill new leadership role, bringing with her expertise in blood disorders and clinical practice.

Results from multicenter study are first to show improved production of coagulation factor VIII over prolonged period, leading to reduction or complete elimination of bleeding events.

A collaborative team of researchers, including Dr. Stephan Grupp, recently presented preliminary data showing that a CRISPR-based gene-editing therapy for inherited blood disorders is safe and effective.

Kwaku Ohene-Frempong, MD was named a 2021 Honorific Award Recipient by the American Society of Hematology.

CHOP researchers have developed a proof-of-concept treatment for blood disorders like sickle cell disease that elevates both fetal and adult hemoglobin.

CHOP researchers were interviewed as a part of a comprehensive article about cell and gene therapy in Philadelphia Magazine.

CHOP researchers have identified BAFF as a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A.